Semin Vasc Med 2003; 03(2): 163-176
DOI: 10.1055/s-2003-40674
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Combined Antithrombotic Therapy for Acute Coronary Syndrome

Meinrad Gawaz, Iris Müller, Felicitas Besta
  • Deutsches Herzzentrum and 1. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
Further Information

Publication History

Publication Date:
18 July 2003 (online)


Remarkable therapeutic advances in the treatment of acute coronary syndromes (ACS) have been made with combined antithrombotic therapy. Aspirin is accepted as standard therapy in the management of ACS but has significant limitations, including intolerance, resistance, and peptic ulceration. With the intravenous platelet glycoprotein IIb/IIIa inhibitors and the new thienopyridine clopidogrel, the options for acute and chronic antiplatelet therapy have expanded. Recently, the combination of antiplatelet therapy and oral anticoagulation has gained much interest and has been shown to be effective in secondary prevention of ACS. This article summarizes important recent findings on the background of existing pathological and clinical knowledge to provide an understanding of the basis of current combined antithrombotic therapy.


  • 1 Hamm C W, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines.  Lancet . 2001;  358 1533-1538
  • 2 Gawaz M. Platelets and primary hemostasis. In: Blood Platelets Stuttgart: Thieme 2001
  • 3 Schrör K. Antiplatelet drugs. A comparative review.  Drugs . 1995;  50 7-28
  • 4 Crowther M A, Ginsberg J S, Hirsh J. Practical aspects of anticoagulant therapy. In: Robert W, Colman et al., eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice, 4th ed. Philadelphia, Baltimore, New York: Lippincott Williams & Wilkins 2000
  • 5 Holme P A, Orvim U, Hamers M J. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis.  Arterioscler Thromb Vasc Biol . 1997;  17 646-653
  • 6 Kroll M H, Hellums J D, McIntire L V, Schafer A I, Moake J L. Platelets and shear stress.  Blood . 1996;  88 1525-1541
  • 7 Ruggeri Z M. New insights into the mechanisms of platelet adhesion and aggregation.  Semin Hematol . 1994;  31 229-239
  • 8 Clemetson K J, Clemetson J M. Platelet collagen receptors.  Thromb Haemost . 2001;  86 189-197
  • 9 Massberg S, Gawaz M, Grüner S. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo.  J Exp Med . 2003;  197 41-49
  • 10 Mehta P. Aspirin in the prophylaxis of coronary artery disease.  Curr Opin Cardiol . 2002;  17 552-558
  • 11 Weber A A, Zimmermann K C, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.  Lancet . 1999;  353 900
  • 12 Helgason C M, Bolin K M, Hoff J A. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke . 1994;  25 2331-2336
  • 13 Cambria-Kiely J A, Gandhi P J. Possible mechanisms of aspirin resistance.  J Thromb Thrombolysis . 2002;  13 49-56
  • 14 Howard P A. Aspirin resistance.  Ann Pharmacother . 2002;  36 1620-1624
  • 15 Gum P A, Kottke-Marchant K, Poggio E D. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol . 2001;  88 230-235
  • 16 Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.  Circulation . 2002;  105 1650-1655
  • 17 Weber A A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: a typological approach.  Platelets . 2002;  13 37-40
  • 18 CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).  Lancet . 1996;  384 1329-1339
  • 19 Müller I, Seyfarth M, Rüdiger S. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.  Heart . 2001;  85 92-93
  • 20 The ESPS-2 Group. European stroke prevention study 2: efficacy and safety data.  J Neurol Sci . 1997;  151 41-51
  • 21 Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  Br Med J . 2002;  324 71-86
  • 22 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy.  Br Med J . 1994;  308 159-168
  • 23 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  Br Med J . 1994;  308 81-106
  • 24 Helgason C M, Bolin K M, Hoff J A. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke . 1994;  25 2331-2336
  • 25 Schömig A, Neumann F J, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.  N Engl J Med . 1996;  334 1084-1089
  • 26 Leon M B, Baim D S, Popma J J. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.  N Engl J Med . 1998;  339 1665-1671
  • 27 Urban P, Macaya C, Rupprecht H J. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).  Circulation . 1998;  98 2126-2132
  • 28 Bertrand M E, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.  Circulation . 1998;  98 1597-1603
  • 29 Bertrand M E, Rupprecht H J, Urban P, Gershlick A H, Investigators F T. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).  Circulation . 2000;  102 624-629
  • 30 Moussa I, Oetgen M, Roubin G. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.  Circulation . 1999;  99 2364-2366
  • 31 Berger P B, Bell M R, Rihal C S. Clopidogrel versus ticlopidine after intracoronary stent placement.  J Am Coll Cardiol . 1999;  34 1891-1894
  • 32 Mishkel G J, Aguirre F V, Ligon R W, Rocha-Singh K J, Lucore C L. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.  J Am Coll Cardiol . 1999;  34 1884-1890
  • 33 Steinhubl S R, Berger P B, Mann III T J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO).  JAMA . 2002;  288 2411-2420
  • 34 Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G, Fox K K, The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med . 2001;  345 494-502
  • 35 Mehta S R, Yusuf S, CURE Study Investigators. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.  Eur Heart J . 2000;  24 2033-2041
  • 36 Mehta S R, Yusuf S, Peters R J. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet . 2001;  358 527-533
  • 37 Gawaz M, Seyfarth M, Müller I. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement.  Am J Cardiol . 2001;  87 332-336
  • 38 Steinhubl S R, Lauer M S, Mukherjee D P. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.  J Am Coll Cardiol . 1998;  32 1366-1370
  • 39 Steinhubl S R, Ellis S G, Wolski K, Lincoff A M, Topol E J. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.  Circulation . 2001;  103 1403-1409
  • 40 Järemo P, Lindahl T L, Fransson S G, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel.  J Int Med . 2002;  252 233-238
  • 41 Quinn M J, Plow E F, Topol E J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?.  Circulation . 2002;  106 379-385
  • 42 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy.  N Engl J Med . 1998;  339 436-443
  • 43 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998 338: 1488-1497
  • 44 Patel M R, Roe M T. Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation.  Drugs Aging . 2002;  19 633-646
  • 45 Simoons M L, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.  Lancet . 2001;  357 1915-1924
  • 46 Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997 349: 1429-1435
  • 47 Cannon C P, Weintraub W S, Demopoulos L A. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.  N Engl J Med . 2001;  344 1879-1887
  • 48 Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during instability in coronary artery disease.  Lancet . 2000;  356 9-16
  • 49 Moliterno D J, Yakubov S J, DiBattiste P M. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.  Lancet . 2002;  360 355-360
  • 50 Topol E J, Mark D B, Lincoff A M. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting.  Lancet . 1999;  354 2019-2024
  • 51 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.  Lancet . 1990;  336 827-830
  • 52 Holdright D, Patel D, Cunningham D. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.  J Am Coll Cardiol . 1994;  24 39-45
  • 53 Wallis D E, Boden W E, Califf R. Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina.  Am Heart J . 1991;  122 949-954
  • 54 Oler A, Whooley M A, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.  JAMA . 1996;  276 811-815
  • 55 Cohen M, Demers C, Gurfinkel E P. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events.  Am J Cardiol . 1998;  82 19L-24L
  • 56 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.  Circulation . 1999;  100 1593-1601
  • 57 Antman E M, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.  Circulation . 1999;  100 1602-1608
  • 58 Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.  Lancet . 1999;  353 429-438
  • 59 Brouwer M A, Verheugt F WA. Oral anticoagulation for acute coronary syndromes.  Circulation . 2002;  105 1270-1274
  • 60 Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction.  Lancet . 1997;  350 389-396
  • 61 Fiore L D, Ezekowitz M D, Brophy M T, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.  Circulation . 2002;  105 557-563
  • 62 van Es F R, Jonker J J, Verheugt F W, Deckers J W, Grobbee D E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.  Lancet . 2002;  360 109-113
  • 63 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction.  N Engl J Med . 2002;  347 969-974
  • 64 Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery.  Circulation . 2001;  103 3069-3074
  • 65 The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina.  J Am Coll Cardiol . 2001;  37 475-484
  • 66 Anand S S, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.  JAMA . 1999;  282 2058-2067
  • 67 Vinik A, Flemmer M. Diabetes and macrovascular disease.  J Diabetes Compl . 2002;  16 235-245
  • 68 Tschoepe D, Driesch E, Schwippert B, Lampeter E F. Activated platelets in subjects at increased risk of IDDM. Denis study group.  Diabetologia . 1997;  40 573-577
  • 69 Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte cross-talk in diabetes mellitus.  Horm Metab Res . 1997;  29 631-635
  • 70 Davi G, Gresele P, Violi F. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.  Circulation . 1997;  96 69-75
  • 71 Shechter M, Merz C N, Paul-Labrador M J, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease.  J Am Coll Cardiol . 2000;  35 300-307
  • 72 Bhatt D L, Marso S P, Lincoff A M, Wolski K E, Ellis S G, Topol E J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention.  J Am Coll Cardiol . 2000;  35 922-928
  • 73 Marso S P, Lincoff A M, Ellis S G. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.  Circulation . 1999;  100 2477-2484
  • 74 Roffi M, Chew D P, Mukherjee D. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.  Circulation . 2001;  104 2767-2771
  • 75 Bhatt D L, Marso S P, Hiesh A T, Ringleb P A, Hacke W, Topol E J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.  Am J Cardiol . 2002;  90 625-628